Abstract
The 2´3´-dialdehyde of ATP or oxidized ATP (oATP) is a compound known for specifically making covalent bonds with the nucleotide-binding site of several ATP-binding enzymes and receptors. We investigated the effects of oATP and other oxidized purines on HIV-1 infection and we found that this compound inhibits HIV-1 and SIV infection by blocking early steps of virus replication. oATP, oxidized ADP (oADP), and oxidized Adenosine (oADO) impact the natural activity of endogenous reverse transcriptase enzyme (RT) in cell free virus particles and are able to inhibit viral replication in different cell types when added to the cell cultures either before or after infection. We used UFLC-UV to show that both oADO and oATP can be detected in the cell after being added in the extracellular medium. oATP also suppresses RT activity and replication of the HIV-1 resistant variants M184V and T215Y. We conclude that oATP, oADP and oADO display anti HIV-1 activity that is at in least in part due to inhibitory activity on HIV-1 RT.
Keywords: HIV-1, macrophage, oxidized adenosine, oxidized ADP, oxidized ATP, reverse transcriptase.
Graphical Abstract
Current HIV Research
Title:2´,3´-Dialdehyde of ATP, ADP, and Adenosine Inhibit HIV-1 Reverse Transcriptase and HIV-1 Replication
Volume: 12 Issue: 5
Author(s): Julieta Schachter, Ana Luiza Chaves Valadao, Renato Santana Aguiar, Victor Barreto-de-Souza, Atila Duque Rossi, Pablo Ricardo Arantes, Hugo Verli, Paula Gabriela Quintana, Norton Heise, Amilcar Tanuri, Dumith Chequer Bou-Habib and Pedro Muanis Persechini
Affiliation:
Keywords: HIV-1, macrophage, oxidized adenosine, oxidized ADP, oxidized ATP, reverse transcriptase.
Abstract: The 2´3´-dialdehyde of ATP or oxidized ATP (oATP) is a compound known for specifically making covalent bonds with the nucleotide-binding site of several ATP-binding enzymes and receptors. We investigated the effects of oATP and other oxidized purines on HIV-1 infection and we found that this compound inhibits HIV-1 and SIV infection by blocking early steps of virus replication. oATP, oxidized ADP (oADP), and oxidized Adenosine (oADO) impact the natural activity of endogenous reverse transcriptase enzyme (RT) in cell free virus particles and are able to inhibit viral replication in different cell types when added to the cell cultures either before or after infection. We used UFLC-UV to show that both oADO and oATP can be detected in the cell after being added in the extracellular medium. oATP also suppresses RT activity and replication of the HIV-1 resistant variants M184V and T215Y. We conclude that oATP, oADP and oADO display anti HIV-1 activity that is at in least in part due to inhibitory activity on HIV-1 RT.
Export Options
About this article
Cite this article as:
Schachter Julieta, Valadao Luiza Chaves Ana, Aguiar Santana Renato, Barreto-de-Souza Victor, Rossi Duque Atila, Arantes Ricardo Pablo, Verli Hugo, Quintana Gabriela Paula, Heise Norton, Tanuri Amilcar, Bou-Habib Chequer Dumith and Persechini Muanis Pedro, 2´,3´-Dialdehyde of ATP, ADP, and Adenosine Inhibit HIV-1 Reverse Transcriptase and HIV-1 Replication, Current HIV Research 2014; 12 (5) . https://dx.doi.org/10.2174/1570162X12666140826105824
DOI https://dx.doi.org/10.2174/1570162X12666140826105824 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Exploring the Role of Phytochemicals as Potent Natural Photosensitizers in Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Organoselenium Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Design of Telomerase Inhibitors for the Treatment of Cancer
Current Pharmaceutical Design Destroying RNA as a Therapeutic Approach
Current Medicinal Chemistry Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design Oxidative Stress Upregulates PDCD4 Expression in Patients with Gastric Cancer via miR-21
Current Pharmaceutical Design 2D QSAR and Virtual Screening based on Pyridopyrimidine Analogs of Epidermal Growth Factor Receptor Tyrosine Kinase
Current Computer-Aided Drug Design Editorial [Hot Topic: TGF-β As Target in Oncology (Guest Editor: Karl-Hermann Schlingensiepen)]
Current Pharmaceutical Biotechnology Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Current Pharmaceutical Design Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) P2Y Receptor Activation Affects the Proliferation and Differentiation of Glial and Neuronal Cells: A Focus on Rat C6 Glioma Cells
Current Neuropharmacology Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents
Current Medicinal Chemistry Diarylurea: A Privileged Scaffold in Drug Discovery and Therapeutic Development
Current Medicinal Chemistry Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Patent Selections:
Current Biomarkers (Discontinued) Therapy Based on the Regulation of Thiol-dependent Redox Systems
Current Medicinal Chemistry